Advances in Immunology
- 1st Edition, Volume 148 - November 25, 2020
- Latest edition
- Editor: Frederick W. Alt
- Language: English
Advances in Immunology, Volume 148 offers the latest release in a long-established and highly respected publication, presenting current developments and comprehensive review… Read more
Advances in Immunology, Volume 148 offers the latest release in a long-established and highly respected publication, presenting current developments and comprehensive reviews in immunology. Sections in this new volume include chapters on histone deacetylases as targets in autoimmune and autoinflammatory diseases, the role of NK cell as central communicators in cancer immunity, and the mechanism and regulation of class switch recombination by transcriptional control element.
- Presents current developments and comprehensive reviews in immunology
- Provides the latest in a longstanding, respected serial on the subject matter
- Focuses on recent advances in the advancing area of the mechanisms involved in the evolution of HIV-1 neutralizing antibodies
Immunologists and infectious disease specialists, cell biologists and hematologists
1. Histone deacetylases as targets in autoimmune and autoinflammatory diseasesPatricia Hamminger, Ramona Rica and Wilfried Ellmeier2. The role of NK cell as central communicators in cancer immunityTobias Bald, Anna-Marie Pedde, Dillon Corvino and Jan P. Böttcher3. Mechanism and regulation of class switch recombination by IgH transcriptional control elementChloe Oudinet, Fatima-Zohra Braikia, Audrey Dauba and Ahmed Amine Khamlichi
- Edition: 1
- Latest edition
- Volume: 148
- Published: November 25, 2020
- Language: English
FA
Frederick W. Alt
Frederick W. Alt is a Howard Hughes Medical Institute (HHMI) Investigator and Director of the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital (BCH). He is the Charles A. Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School. He works on elucidating mechanisms that generate antigen receptor diversity and, more generally, on mechanisms that generate and suppress genomic instability in mammalian cells, with a focus on the immune and nervous systems. Recently, his group has developed senstive genome-wide approaches to identify mechanisms of DNA breaks and rearrangements in normal and cancer cells. He has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the European Molecular Biology Organization. His awards include the Albert Szent-Gyorgyi Prize for Progress in Cancer Research, the Novartis Prize for Basic Immunology, the Lewis S. Rosensteil Prize for Distinugished work in Biomedical Sciences, the Paul Berg and Arthur Kornberg Lifetime Achievement Award in Biomedical Sciences, and the William Silan Lifetime Achievement Award in Mentoring from Harvard Medical School.
Affiliations and expertise
Investigator and Director, Program in Cellular and Molecular Medicine, Howard Hughes Medical Institute Research Laboratories, The Children's Hospital, Boston, MA, USARead Advances in Immunology on ScienceDirect